Skip to main content
Top
Published in: Journal of Clinical Immunology 3/2022

01-04-2022 | Vasculitis | Letter to Editor

Activated PI3 Kinase Delta Syndrome Revealed by Vasculitis and Disseminated Toxoplasmosis

Authors: Aurore Larrauffie, Charlotte Syrykh, Suzanne Tavitian, Thibault Comont, Jeremie Dion

Published in: Journal of Clinical Immunology | Issue 3/2022

Login to get access

Excerpt

Activated phosphoinositide-3kinase delta syndrome (APDS) includes two monogenic immunodeficiencies leading to constitutional activation of the PIK3 pathway. APDS-1 is caused by heterozygous gain-of-function mutation in PIK3CD that induce hyperactivation of the protein subunit p110δ whereas APDS-2 result from the loss of function in PIK3R1 that encodes for p85α regulatory subunit [1, 2]. Clinical manifestations include a lymphoproliferative syndrome with benign lymphadenopathy, splenomegaly, and an increased risk of B cell lymphoma. Infectious complications are common with recurrent respiratory tract infections, bronchiectasis, and opportunistic infections such as chronic Herpes virus infections. Associated autoimmune diseases are also frequent. We herein describe a case of APDS-1 revealed in the adulthood by disseminated toxoplasmosis and vasculitis, both rare and poorly described manifestations of APDS. …
Appendix
Available only for authorised users
Literature
1.
go back to reference Angulo I, Vadas O, Garçon F, Banham-Hall E, Plagnol V, Leahy TR, et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science [Internet]. 2013 Nov 15 [cited 2021 Sep 6]; Available from: https://www.science.org/doi/abs/https://doi.org/10.1126/science.1243292 Angulo I, Vadas O, Garçon F, Banham-Hall E, Plagnol V, Leahy TR, et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science [Internet]. 2013 Nov 15 [cited 2021 Sep 6]; Available from: https://​www.​science.​org/​doi/​abs/​https://​doi.​org/​10.​1126/​science.​1243292
2.
go back to reference Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: a large patient cohort study. J Allergy Clin Immunol. 2017;139(2):597-606.e4.CrossRefPubMedPubMedCentral Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: a large patient cohort study. J Allergy Clin Immunol. 2017;139(2):597-606.e4.CrossRefPubMedPubMedCentral
3.
go back to reference Karanovic D, Michelow IC, Hayward AR, DeRavin SS, Delmonte OM, Grigg ME, et al. Disseminated and congenital toxoplasmosis in a mother and child with activated PI3-kinase δ syndrome type 2 (APDS2): case report and a literature review of toxoplasma infections in primary immunodeficiencies. Front Immunol. 2019;10:77.CrossRefPubMedPubMedCentral Karanovic D, Michelow IC, Hayward AR, DeRavin SS, Delmonte OM, Grigg ME, et al. Disseminated and congenital toxoplasmosis in a mother and child with activated PI3-kinase δ syndrome type 2 (APDS2): case report and a literature review of toxoplasma infections in primary immunodeficiencies. Front Immunol. 2019;10:77.CrossRefPubMedPubMedCentral
5.
go back to reference Hong Y, Nanthapisal S, Omoyinmi E, Olbrich P, Neth O, Speckmann C, et al. Secondary C1q deficiency in activated PI3Kδ syndrome type 2. Front Immunol. 2019;10:2589.CrossRefPubMedPubMedCentral Hong Y, Nanthapisal S, Omoyinmi E, Olbrich P, Neth O, Speckmann C, et al. Secondary C1q deficiency in activated PI3Kδ syndrome type 2. Front Immunol. 2019;10:2589.CrossRefPubMedPubMedCentral
Metadata
Title
Activated PI3 Kinase Delta Syndrome Revealed by Vasculitis and Disseminated Toxoplasmosis
Authors
Aurore Larrauffie
Charlotte Syrykh
Suzanne Tavitian
Thibault Comont
Jeremie Dion
Publication date
01-04-2022
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 3/2022
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-021-01186-1

Other articles of this Issue 3/2022

Journal of Clinical Immunology 3/2022 Go to the issue